January 1, 2016 – AskAt Inc. (AskAt), headquartered in Nagoya, Japan, today announced license agreements with RMX Pharmaceutical Technology Co., Ltd. (RMX), headquartered in Hangzhou, Zheijiang Province, People’s Republic of China (China), granting RMX exclusive rights to develop, manufacture and commercialize AskAt’s EP4 Antagonist [AAT-007] and COX-2 Inhibitor [AAT-076] in China for Pain. Under the terms of the signed agreements, AskAt will receive upfront payments from RMX and is eligible to receive Development and Commercial Milestone payments and Royalties on sales of products in China.
AAT-007 is a novel prostaglandin EP4 antagonist that has exhibited robust pre-clinical and clinical analgesic efficacy in chronic inflammatory pain. In a 4-week Phase-2 osteoarthritis pain study, AAT-007 75 mg BID exhibited equivalent efficacy to Naproxen 500 mg BID, with a significant GI safety advantage. In addition to Pain, the EP4 antagonist has additional development opportunities for immune-oncology and auto-immune diseases.
AAT-076 is a COX-2 inhibitor, uniquely differentiated from non-steroidal and non-narcotic drugs, for the treatment of acute pain and post-operative pain. Available pre-clinical and clinical data suggest AAT-076 is a powerful pain medication with safety advantages, e.g., renal and CV, over existing NSAIDs and COXIBs, as well as the potential for neuropathic pain states. Additionally, AAT-076’s potency, rapid analgesia onset, and long-lasting analgesic effects provide superior pain relief with the opportunity for opioid sparing.
AskAt is a new kind of life sciences company, an open collaboration catalyst, with a team of highly dedicated and experienced professionals. AskAt accelerates innovation in small molecule R&D by designing and implementing highly optimized platforms, value-enhancing life cycle partnering opportunities, around its core intellectual property. AskAt’s R&D programs are focused on areas of critical, unmet patient needs, including cancer, Alzheimer’s Disease, pain, autoimmune disorders, and blindness caused by macular degeneration. For more information, please contact us at email@example.com .
RMX is a pharmaceutical R&D company comprised of experienced and dedicated experts working with multinational and local pharmaceutical companies with a demonstrated track record of success. RMX develops innovative medicines to target unmet medical needs in North East Asia, including China, Japan, Korea, Taiwan and Hong Kong. RMX’s development portfolio focuses on oncology, infectious disease and CNS/pain. For more information, please contact us at firstname.lastname@example.org .